Studies of melatonin in people
91 studies gave melatonin to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases ghrelin4.35 ± 0.90 pg/mL vs. 4.78 ± 0.75 pg/mL; p = 0.013 no change: Has no effect on 2-arachidonoylglycerol no change: Has no effect on hedonic appetite intensity | Randomized trial8 weeks | 41 peopleWomen35.68 ± 7.51 yearsOverweight or obesity and high hedonic appetite | Scientific reports, Oct 18, 2026 |
down: Decreases low-density lipoprotein cholesterol down: Decreases triglyceride | Randomized trial12 weeks | 38 peopleWomenPostmenopausal women | Experimental gerontology, Oct 10, 2026 |
up: Increases bone mineral density up: Improves quality of life | Randomized trial6 months | 60 peopleWomen≥45 yearsMidlife adults; Older adults; Postmenopausal women; with calcium and vitamin D supplementation | International Journal of Drug Delivery Technology, Jun 29, 2026 |
up: Improves leg muscle strength up: Improves unipedal static balance | Randomized trial12 weeks | 36 peoplePost-intervention | International journal of food sciences and nutrition, Jun 24, 2026 |
| Randomized trialeight weeks | 200 peopleBothaged 18 to 50 yearsAdults aged 18 to 50 years who met the DSM-5 diagnostic criteria for sleep disturbance | Clocks & sleep, Mar 27, 2026 | |
down: Decreases protein carbonyls up: Increases ferric reducing ability of plasma | Randomized trialthree months | 51 peopleWomenIn PCOS patients receiving metformin | Journal of gynecology obstetrics and human reproduction, Mar 23, 2026 |
down: Decreases climacteric symptoms−15.8% vs +33.5% up: Improves sleep quality no change: Has no effect on total sleep duration | Randomized trial3 months | 46 peoplewomenmean age 47.2 ± 5.4 years, range 39–60 yearsWomen in the climacteric who worked fixed-shifts | Journal of pineal research, Mar 1, 2026 |
up: Improves subjective psychological well-being | Randomized trial28 days | 59 people30–60 yearsMidlife adults; healthy adults with poor sleep quality | Preprints.org, Feb 11, 2026 |
no change: Has no effect on delirium3.64% vs 1.85%, p=1.000 no change: Has no effect on sleep durationp=0.136 no change: Has no effect on mortality3.64% vs 1.85%, p=1.000 | Randomized trialup to 5 days | 109 people≥65 yearsOlder adults; medically hospitalised older patients | BMJ open, Jan 27, 2026 |
| Trial | Hospitalized patients; before-and-after comparison | Cureus, Dec 31, 2025 | |
no change: Has no effect on sleep quality no change: Has no effect on sleep efficiency | Randomized trial30 days | 64 people40 to 80 yearsMidlife adults; Older adults; advanced primary open-angle glaucoma | Ophthalmology. Glaucoma, Dec 11, 2025 |
down: Decreases hot flashes up: Improves quality of life up: Improves sexual function | Randomized trialfour weeks | 60 peopleAdultBreast cancer patients receiving antihormone medications | Advanced biomedical research, Oct 31, 2025 |
no change: Has no effect on anthropometry no change: Has no effect on physical function no change: Has no effect on health-related quality of life | Randomized trial10 weeks | 10 peopleWomen60–75 yearsOlder adults; Postmenopausal women; Breast cancer survivors receiving an adapted physical activity program | Frontiers in sports and active living, Jun 23, 2025 |
up: Improves best-corrected visual acuity down: Decreases choroidal vascularity index | Trialone month | 14 peoplePatients with CSCR | Cureus, Dec 29, 2024 |
no change: Has no effect on postoperative neurocognitive disorder | Randomized trialthe night before surgery and the first three postoperative nights | 176 peoplemales≥ 60 yearsPatients aged ≥ 60 undergoing elective TURP under spinal anesthesia | Clinics (Sao Paulo, Brazil), Dec 26, 2024 |
down: Decreases oxidative stress markers up: Improves mitochondrial function | Treated cohort≥ 8 weeks | 161 peopleWomen35–45 yearsMidlife adults | Reproductive biology and endocrinology : RB&E, Nov 8, 2024 |
no change: Has no effect on cognitive function | Randomized trial12 weeks | 40 peopleBoth68.2 [4.7] yearsOlder adults; Mild Cognitive Impairment | Journal of pineal research, Nov 1, 2024 |
up: Improves sleep onset latency7:04 min faster compared with placebo up: Increases total sleep timeabout 30 min up: Increases cortisol | Randomized trial2 days (crossover design) | 64 peopleaverage age was 41.11 years oldHealthy volunteers aged at least 18 years | Pharmacology research & perspectives, Jun 1, 2024 |
no change: Has no effect on sleep disturbance down: Decreases sleep disturbance down: Decreases pain0.24, 95% CI 0.08–0.39 | Randomized trial6 weeks | 58 peopleBothPatients with severe chronic pain for at least 3 months | British journal of anaesthesia, Feb 14, 2024 |
no change: Has no effect on type 2 diabetes no change: Has no effect on fat intake | Randomized trial12 weeks | 27 peopleWomenPatient cohorts | Frontiers in nutrition, Jan 22, 2024 |
no change: Has no effect on insulin resistance no change: Has no effect on diurnal blood pressure up: Improves sleep qualityp < 0.001 | Randomized trial12 weeks | 24 people | Pharmacological research, Nov 27, 2023 |
up: Improves exercise capacity71 ± 26 vs. 25 ± 36 m, p < 0.01 up: Improves health status-11 ± 6 vs. -3 ± 5, p < 0.01 up: Improves quality of life-6.9 ± 3.0 vs. -1.9 ± 2.4, p < 0.01 | Randomized trial12 weeks | 39 peopleDuring pulmonary rehabilitation in patients with COPD | Respiratory medicine, Nov 7, 2023 |
down: Decreases nighttime systolic blood pressure100 ± 10 vs 105 ± 10 mmHg, P = 0.01 no change: Has no effect on 24-h mean arterial pressure82 ± 5 vs 83 ± 6 mmHg, P = 0.23 no change: Has no effect on blood pressure reactivityall P > 0.05 | Randomized trial10 days | 22 peopleBoth26.5 ± 3.1 yrGeneral population; on a high-sodium diet | American journal of physiology. Regulatory, integrative and comparative physiology, Aug 29, 2023 |
up: Improves quality of life | Randomized trial12 weeks | 33 peopleIn hemodialysis patients | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, Feb 9, 2023 |
no change: Has no effect on sleep qualityPSQI 5.6 vs 6.1, P = 0.615 no change: Has no effect on pain no change: Has no effect on quality of life | Randomized trial4 weeks | 84 peoplemean age 41.8 ± 15.5 years and 41.3 ± 14.0 yearsPostoperative orthopedic trauma patients | Injury, Oct 14, 2022 |
down: Decreases insulin sensitivitydifference −0.6 [−1.13 to −0.13] mg/(kg × min) | Randomized trialtwo 12‐week treatment periods | 17 peoplemale sexage 40–70 yearsCaucasian men aged 40–70 years with type 2 diabetes | Journal of pineal research, Jun 9, 2022 |
up: Increases stage 2 non-rapid eye movement sleep duration | Randomized trial24 calendar days | 24 people13 women, 11 menmean ± SD: 64.2 ± 6.3 yearsMedically and psychologically healthy older adults | Journal of pineal research, Apr 19, 2022 |
no change: Has no effect on carotid intima-media thicknessP = 0.51, P = 0.16, P = 0.76, P = 0.15 no change: Has no effect on pulse wave velocityP = 0.55 no change: Has no effect on C-reactive proteinP = 0.81 | Randomized trial24 weeks | 32 peopleDiabetic nephropathy | Clinical nutrition ESPEN, Jan 6, 2022 |
down: Decreases sleep disordersP ≤0.001 down: Decreases depressionP ≤0.001 down: Decreases anxietyP = 0.001 | Randomized trial3 months | 60 peoplePatient cohorts | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, Jan 1, 2022 |
up: Increases ventilator-free days16.90 ± 9.24 days in the melatonin group vs. 10.00 ± 10.94 days in the placebo group down: Decreases vasopressor requirement6.21 ± 5.12 reduction vs 3.20 ± 3.95 reduction up: Increases vasopressor-free days12.75 ± 7.43 days vs. 10.15 ± 6.12 days | Randomized trialfive consecutive nights | 40 people67.5% of the patients were men54.9 ± 12.21 yearsAdult patients with early septic shock | Irish journal of medical science, Sep 1, 2021 |
down: Decreases body weight down: Decreases body fat mass percentage | Randomized trial12 weeks | 44 peopleBothPatient cohorts | BioMed research international, Aug 10, 2021 |
down: Decreases body weight | Randomized trial12 weeks | 27 peopleWomen37.1 yo, ±5.9 yoIn early chronotypes | Journal of pineal research, Jun 20, 2021 |
down: Decreases pittsburgh Sleep Quality Index score up: Increases HDL-C2.76 mg/dl [95% CI 0.57, 4.95] | Randomized trial8 weeks | 84 peopleWomen18-40 yearsWomen with PCOS, compared with baseline | Nutrition & metabolism, Jun 6, 2021 |
down: Decreases TNF-alphaP < 0.05 | Randomized trial8 weeks | 84 peopleWomen18-40 years oldIn women with polycystic ovary syndrome | Biological trace element research, May 19, 2021 |
down: Decreases poor-quality embryos0.27 vs. 0.80, P = 0.028 no change: Has no effect on clinical pregnancy rate14% vs. 7%, P = 0.302 | Trial | 90 peopleBothInfertile couples undergoing IVF | Naunyn-Schmiedeberg's archives of pharmacology, Mar 8, 2021 |
down: Decreases malondialdehydeP<0.001 down: Decreases LDL cholesterolP=0.007 no change: Has no effect on rheumatoid arthritisP>0.05 | Randomized trial12 weeks | 64 peoplePatient cohorts | Clinical rheumatology, Mar 5, 2021 |
no change: Has no effect on cardio-ankle vascular index no change: Has no effect on mitochondrial DNA copy number no change: Has no effect on HOMA-IR | Randomized trialsix weeks | 38 peopleAll subjects were women55 years and olderWomen over 55 years old with insomnia | International journal of environmental research and public health, Mar 4, 2021 |
down: Decreases fasting blood glucoseβ = -10.64 mg/dL; 95% CI: -20.37 to -0.90; P < .05 up: Increases HDL cholesterolβ = 2.75 mg/dL, 95% CI: 0.75 to 4.75; P < .05 up: Increases total antioxidant capacityβ = 140.45 mmol/L; 95% CI: 80.48 to 200.41; P < .001 | Randomized trial12 weeks | 60 peopleIn patients with diabetic nephropathy | Iranian journal of kidney diseases, Jan 1, 2021 |
up: Improves sleep quality69.7 vs 60.7, p = 0.029 down: Lowers the risk of poor sleepRR 0.21, 95% CI 0.06-0.71 no change: Has no effect on delirium | Randomized trialup to seven consecutive nights | 203 peopleadultCritically ill ICU patients | Critical care medicine, Dec 1, 2020 |
down: Decreases disease severityβ -2.33, 95% CI -3.57 to -1.09 down: Decreases C-reactive proteinβ -0.94 mg/L, 95% CI -1.55 to -0.32 up: Increases total antioxidant capacityβ 108.09 mmol/L, 95% CI 78.21 to 137.97 | Randomized trial12 weeks | 60 peopleIn patients with Parkinson's disease | Clinical neurology and neurosurgery, May 1, 2020 |